James Verco
15 Papers
36 Citations
James Verco is an academic researcher. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 3, co-authored 12 publications.
Chat about Author
Papers
Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model.
James Verco,William Johnston,Michael Baltezor,Philip J. Kuehl,Andrew P. Gigliotti,Steven A. Belinsky,Anita Lopez,Ronald Wolff,Lauren Hylle,Gere S. diZerega +9 more
TL;DR: In the rodent model, inhaled NanoPac demonstrated substantial deposition and retention of paclitaxel in sampled lung tissue and resulted in an order of magnitude increase in dose-normalized pulmonary exposure over IVnP.
23
Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies
Shelagh Verco,Holly Maulhardt,Michael Baltezor,Emily Williams,Marc Iacobucci,Alison Wendt,James Verco,Alyson Marin,Sam Campbell,Paul Dorman,Gere S. diZerega +10 more
TL;DR: Results of preclinical and clinical investigations described here suggest that local administration of SPP achieves clinical benefit with negligible toxicity and may complement standard treatments for metastatic disease.
Inhaled Submicron Particle Paclitaxel (NanoPac) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer
James Verco,William Johnston,Michael V Frost,Michael Baltezor,Philip J. Kuehl,Anita Lopez,Andrew P. Gigliotti,Steven A. Belinsky,Ronald Wolff,Gere S. diZerega +9 more
TL;DR: Tumor regression and immune cell infiltration were observed in all treatment groups, with an increased incidence noted in animals receiving IH submicron particle paclitaxel treatment.
13
Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical Outcome.
Neil R Sharma,Simon K Lo,Andrew Eugene Hendifar,Mohamed O Othman,Kalpesh Patel,Antonio Mendoza-Ladd,Shelagh Verco,Holly Maulhardt,James Verco,Alison Wendt,Alyson Marin,Christian Max Schmidt,Gere DiZerega +12 more
TL;DR: Neoadjuvant IT LSAM-PTX, in combination with SOC, was well tolerated and may provide benefits to LAPC patients, evidenced by enhanced immune response, improved disease control rate, restaging leading to surgery, and extended survival.
7
Patent
Methods for Treating Lung Disorders
Michael Baltezor,Matthew Mcclorey,William Johnston,Gere S. diZerega,James Verco +4 more
- 13 Jun 2018
TL;DR: In this paper, compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles are presented.
4